Multi-cancer early detection (MCED)
Multi-cancer early detection (MCED) screens asymptomatic, average-risk individuals from a single blood draw for molecular signals shared across dozens of cancer types — a population-screening scenario distinct from companion-therapy diagnostics. The technology base is circulating-DNA, methylation-pattern and protein-signal analysis. Analytical instrumentation for nucleic-acid and protein-marker research is procured.
Procurement category: laboratory & analytical equipment. Bioecon selects suppliers and organises supply in this category to the customer's brief. Catalogue-level entry: the specific manufacturer, configuration and specification are determined at the enquiry stage. Price — on request.
| Category slug | lab-analytical |
|---|---|
| Cluster | diagnostics-medtech |
| Article | multi-cancer-early-detection |
| Identifier | bio.eqp.multi-cancer-early-detection.lab-analytical |
| CPV | 38430000 |
| OKPD2 | 32.50 |
| NAICS | 334516 |
| UNSPSC | 41121700 |
| CHINA CP | A0320 |
Every item is a procurement category, not a named manufacturer's product. Bioecon is a single seller and holds no stock: supplier selection, configuration and specification are settled at enquiry, and the price is by quote.